Impact of pre-stroke metformin use on prognosis of Ischemic stroke; A pilot study

Document Type: Original Article

Authors

1 Clinician Scientist Current Trainee, Firoozgar Hospital, Student Research Committee,Iran University of Medical Sciences, Tehran, Iran.

2 Firoozgar Hospital, Student Research Committee, Iran University of Medical Sciences. Tehran, Iran.

3 Department of Clinical Pharmacy, Faculty of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.

4 Assistant Professor of Neurology , Iran University of Medical Sciences, Tehran, Iran

10.22034/jbr.2019.97272

Abstract

Introduction: Ischemic stroke can arise from many atherosclerotic events including diabetes mellitus, a worldwide challenge now a day. Many factors have been shown to be effective on improvement of clinical prognosis in diabetic patients with stroke including good glucose control achieves most commonly by Metformin consumption. Metformin is shown previously to decrease the rate of incidence of stroke in diabetic patients, but its effect on clinical prognosis and severity of ischemic stroke in diabetic patients who involve by ischemic stroke has not been evaluated unless in a few researches, making the current research purpose.
 
Method: 40 Diabetic patients who were involved by ischemic stroke were enrolled in our study according to inclusion and exclusion criteria, placed equally 20 patients in each of the groups of our research, the former consisted of diabetic patients who were under glucose control by Metformin and the latter consisted of diabetic patients who were receiving other medications else than Metformin. At the day of stroke and at the end of a three months course, while patients were continuing the previous antidiabetic medical regimens during this course, clinical outcome and severity of diabetic stroke patients evaluated by MRSA and NIHSS respectively.
 
Results:  results showed no statistically significant difference between Metformin consumers and non-consumers in both initial and final MRS scores, means that there is no correlation between Metformin consumption and a better prognosis in diabetic patients with stroke. RTPA consumption were of value for improvement in patients final MRS score means a more favorable outcome.
 
Conclusion: Although Metformin therapy is known as a protective factor in diabetic patients decreasing the risk of ischemic stroke, probably by maintaining the normoglycemic state in patients, despite some previously performed studies results, here we have not found any clinically significant efficacy of Metformin in improvement of clinical outcome and lowering stroke severity in diabetic patients involved by ischemic brain stroke.

Keywords


[1]        Kendall DM, Harmel AP. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am J Manag Care 2002;8(20 Suppl):S635–S653.
 
[2]        Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2): 434–444. [PubMed: 8432214]
 
[3]        Folsom AR, Rasmussen ML, Chambless LE, Howard G, Cooper LS, Schmidt MI, Heiss G. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) study investigators. Diabetes Care 1999;22:1077–1083. [PubMed: 10388971]
 
[4]        Kain K, Catto AJ, Grant PJ (2003) Associations between insulin resistance and thrombotic risk factors in high-risk South Asian subjects. Diabet Med 20:651–655
 
 
[5]        Perez PM, Moore-Carrasco R, Gonzalez DR, Fuentes EQ, Palomo IG (2012) Gene expression of adipose tissue, endothelial cells and Metab Brain Dis platelets in subjects with metabolic syndrome (review). Mol Med Rep 5:1135–1140
 
[6]        Vazzana N, Ranalli P, Cuccurullo C, Davi G (2012) Diabetesmellitus and thrombosis. Thromb Res 129:371–377
 
[7]        Nair SS, Sylaja PN, Sreedharan SE, Sarma S. Maintenance of normoglycemia may improve outcome in acute ischemic stroke. Annals of Indian Academy of Neurology. 2017 Apr;20(2):122.
 
[8]        Zhao L, Wang L, Lu M, Hu W, Xiu S. Hyperglycemia is associated with poor in-hospital outcome in elderly patients with acute ischemic stroke. Medicine. 2019 Aug;98(31).
 
[9]        Mima Y, Kuwashiro T, Yasaka M, Tsurusaki Y, Nakamura A, Wakugawa Y, Okada Y. Impact of metformin on the severity and outcomes of acute ischemic stroke in patients with type 2 diabetes mellitus. Journal of Stroke and Cerebrovascular Diseases. 2016 Feb 1;25(2):436-46.
 
[10]       Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke. 2003 Jan 1;34(1):122-6.
 
[11]       Appelros P, Nydevik I, Seiger A, Terént A. Predictors of severe stroke: influence of preexisting dementia and cardiac disorders. Stroke. 2002 Oct 1;33(10):2357-62.
 
[12]       Cheng YY, Leu HB, Chen TJ, Chen CL, Kuo CH, Lee SD, Kao CL. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. Journal of Stroke and Cerebrovascular Diseases. 2014 Feb 1;23(2):e99-105.
 
[13]       Jin Q, Cheng J, Liu Y, Wu J, Wang X, Wei S, Zhou X, Qin Z, Jia J, Zhen X. Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain, behavior, and immunity. 2014 Aug 1;40:131-42.
 
[14]       Arbeláez-Quintero I, Palacios M. To use or not to use metformin in cerebral ischemia: a review of the
 
[15]       application of metformin in stroke rodents. Stroke research and treatment. 2017;2017.
 
[16]       S. Genuth, R. Eastman, R. Kahn et al., “Implications of the United Kingdom Prospective Diabetes Study,” Diabetes Care, vol. 25, no. 1, pp. S28–S32, 2002.
 
 
[18]       Li J., Benashski S.E., Venna V.R., McCullough L.D. Effects of metformin in experimental stroke. Stroke. 2010;41(11):2645–2652. doi: 10.1161/STROKEAHA.110.589697
 
[19]       Ashabi G., Khalaj L., Khodagholi F., Goudarzvand M., Sarkaki A. Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia. Metab. Brain Dis. 2014
 
[20]       Ashabi G., Khodagholi F., Khalaj L., Goudarzvand M., Nasiri M. Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK/PGC-1α pathway. Metab. Brain Dis. 2014;29(1):47–58. doi: 10.1007/s11011-013-9475-2.
 
[21]       Jiang T., Yu J.T., Zhu X.C., Wang H.F., Tan M.S., Cao L., Zhang Q.Q., Gao L., Shi J.Q., Zhang Y.D., Tan L. Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. Br. J. Pharmacol.2014;171(13):3146–3157.doi: 10.1111/bph.12655.
 
[22]       Elgebaly M.M., Prakash R., Li W., Ogbi S., Johnson M.H., Mezzetti E.M., Fagan S.C., Ergul A. Vascular protection in diabetic stroke: role of matrix metalloprotease-dependent vascular remodeling. J. Cereb. Blood Flow Metab. 2010;30(12):1928–1938. doi: 10.1038/jcbfm.2010.120
 
[23]       Y. Chen, K. Zhou, R. Wang et al., “Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 10, pp. 3907–3912, 2009.